Publications by authors named "Daniel Arnes Garcia"
Article Synopsis
- The text discusses a Gram-positive bacillus, commonly found on the skin, which was previously thought to have minimal pathogenic potential but is now being recognized for its role in serious infections like bacteremia and endocarditis.
- It provides an overview of four cases of endocarditis caused by this bacterium at a hospital between May 2021 and April 2022, highlighting that most patients were men and had existing valve or device implants.
- The findings indicated that the aortic valve was most affected, with a significant proportion of patients undergoing valve replacement and being treated primarily with vancomycin, while noting an overall mortality rate of 21.9% significantly higher in comparison to other reported cases.
Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort.
Daniel Arnés García Inés Pitto-Robles Jorge Calderón Parra Marina Calvo Salvador Carmen Herrero Rodríguez
Antibiotics (Basel)
December 2023
Article Synopsis
- A study compared the effectiveness and safety of ceftaroline fosamil (ceftaroline-F) and ceftobiprole medocaril (ceftobiprole-M) for treating infections in hospitalized patients in Spain.
- Ceftaroline-F was found to be given to younger patients and associated with higher rates of severe infections like bacteremia and infective endocarditis, while ceftobiprole-M was more often used for polymicrobial and Gram-negative infections.
- Both antibiotics had similar infection-related mortality rates and dropout rates due to side effects, but patients on ceftaroline-F had longer hospital stays.
Article Synopsis
- Ceftobiprole medocaril (Cefto-M) is a fifth-generation antibiotic approved in Europe for pneumonia treatment, and a study was conducted in Spain to evaluate its use in clinical practice from September 2021 to December 2022.
- The study included 249 patients, mostly older adults with various infections, with respiratory infections being the most common; 67.9% received Cefto-M as empirical treatment, typically as monotherapy for about one week.
- The results showed an 11.2% infection-related mortality, with higher rates in patients with severe conditions like ventilator-associated pneumonia and sepsis, indicating that Cefto-M is generally safe and often used as a last-resort option